Registered number
11740605
Sander Pharma Limited
Filleted Accounts
31 August 2025

Sander Pharma Limited
Registered number: | 11740605
Balance Sheet
as at 31 August 2025
Notes |  |  | 2025 |  |  | 2024
£ | £
Fixed assets
Intangible assets | 3 |  |  | 266,000 |  |  | 285,000
Tangible assets | 4 |  |  | 12,666 |  |  | 10,833
|  |  |  | 278,666 |  |  | 295,833
Current assets
Stocks |  |  | 45,175 |  |  | 28,533
Debtors | 5 |  | 172,969 |  |  | 87,416
Cash at bank and in hand |  |  | 49,572 |  |  | 89,969
|  |  | 267,716 |  |  | 205,918
Creditors: amounts falling due within one year | 6 |  | (244,408) |  |  | (222,264)
Net current assets/(liabilities) |  |  |  | 23,308 |  |  | (16,346)
Total assets less current liabilities |  |  |  | 301,974 |  |  | 279,487
Creditors: amounts falling due after more than one year | 7 |  |  | (212,952) |  |  | (222,393)
Net assets |  |  |  | 89,022 |  |  | 57,094
Capital and reserves
Called up share capital |  |  |  | 100 |  |  | 100
Profit and loss account |  |  |  | 88,922 |  |  | 56,994
Shareholders' funds |  |  |  | 89,022 |  |  | 57,094
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Mr Viralbhai Kantibhai Patel
Director
Approved by the board on 19 August 2026

Sander Pharma Limited
Notes to the Accounts
for the year ended 31 August 2025
1 | Accounting policies
| Basis of preparation
| The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
| Turnover
| Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
| Intangible fixed assets
| Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.
| Tangible fixed assets
| Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
| Plant and machinery | over 5 years
| Fixtures, fittings, tools and equipment | over 5 years
| Stocks
| Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in first out method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.
| Debtors
| Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
| Creditors
| Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
| Pensions
| Contributions to defined contribution plans are expensed in the period to which they relate.
2 | Employees | 2025 |  | 2024
Number | Number
| Average number of persons employed by the company | 4 |  | 3
3 | Intangible fixed assets | £
| Goodwill:
| Cost
| At 1 September 2024 | 380,000
| At 31 August 2025 | 380,000
| Amortisation
| At 1 September 2024 | 95,000
| Provided during the year | 19,000
| At 31 August 2025 | 114,000
| Net book value
| At 31 August 2025 | 266,000
| At 31 August 2024 | 285,000
| Goodwill is being written off in equal annual instalments over its estimated economic life of 20 years.
4 | Tangible fixed assets
|  |  |  |  |  |  |  | Plant and machinery etc
£
| Cost
| At 1 September 2024 | 34,022
| Additions | 5,000
| At 31 August 2025 | 39,022
| Depreciation
| At 1 September 2024 | 23,189
| Charge for the year | 3,167
| At 31 August 2025 | 26,356
| Net book value
| At 31 August 2025 | 12,666
| At 31 August 2024 | 10,833
5 | Debtors | 2025 |  | 2024
£ | £
| Trade debtors | 52,894 |  | 75,993
| Amounts owed by group undertakings |  | 107,521 |  | -
| Other debtors | 12,554 |  | 11,423
|  |  |  |  |  | 172,969 |  | 87,416
6 | Creditors: amounts falling due within one year | 2025 |  | 2024
£ | £
| Bank loans and overdrafts | 5,619 |  | 5,619
| Trade creditors | 14,745 |  | 4,361
| Taxation and social security costs | 47,276 |  | 37,563
| Other creditors | 112,518 |  | 174,721
|  |  |  |  |  | 244,408 |  | 222,264
7 | Creditors: amounts falling due after one year | 2025 |  | 2024
£ | £
| Bank loans | 212,952 |  | 222,393
8 | Other information
| Sander Pharma Limited is a private company limited by shares and incorporated in England. Its registered office is:
| 36 Camplin Road
| Harrow
| England
| HA3 9LT

Sander Pharma Limited 11740605 false 2024-09-01 2025-08-31 2025-08-31 VT Final Accounts November 2025 Mr Viralbhai Kantibhai Patel No description of principal activity 11740605 2023-09-01 2024-08-31 11740605 core:WithinOneYear 2024-08-31 11740605 core:AfterOneYear 2024-08-31 11740605 core:ShareCapital 2024-08-31 11740605 core:RetainedEarningsAccumulatedLosses 2024-08-31 11740605 2024-09-01 2025-08-31 11740605 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 11740605 bus:AuditExemptWithAccountantsReport 2024-09-01 2025-08-31 11740605 bus:Director40 2024-09-01 2025-08-31 11740605 1 2024-09-01 2025-08-31 11740605 2 2024-09-01 2025-08-31 11740605 core:Goodwill 2024-09-01 2025-08-31 11740605 core:PlantMachinery 2024-09-01 2025-08-31 11740605 countries:England 2024-09-01 2025-08-31 11740605 bus:FRS102 2024-09-01 2025-08-31 11740605 bus:FilletedAccounts 2024-09-01 2025-08-31 11740605 2025-08-31 11740605 core:WithinOneYear 2025-08-31 11740605 core:AfterOneYear 2025-08-31 11740605 core:ShareCapital 2025-08-31 11740605 core:RetainedEarningsAccumulatedLosses 2025-08-31 11740605 core:Goodwill 2025-08-31 11740605 core:PlantMachinery 2025-08-31 11740605 2024-08-31 11740605 core:Goodwill 2024-08-31 11740605 core:PlantMachinery 2024-08-31 iso4217:GBP xbrli:pure